יחס שווי פעילות לרווח לפני ריבית, מסים ופחת: Kairos Pharma Inc (KAPA)

The EV/EBITDA chart on the GURU.Markets platform for Kairos Pharma Ltd (KAPA) reflects a value of 0.00. The business focuses on developing agents that reverse immune blockade in lung and prostate tumors. The operating model relies on external contractors to conduct all testing. The company is currently seeking a financial partner to expand the trials of its portfolio while avoiding merger deals.

Investors in Kairos Pharma Ltd (KAPA) must weigh the business's market value against its operating profit, given the steady demand for drugs targeting therapy resistance. By analyzing the company's EV/EBITDA fluctuations on the GURU.Markets platform, one can assess the impact of debt load on capitalization and identify the risk of margin compression during liquidity shortages, which is critical for asset protection.